Patents by Inventor Tirtha Chakraborty

Tirtha Chakraborty has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220111079
    Abstract: The present invention relates to compositions comprising and methods of using synthetic polynucleotides, e.g., modified mRNA, encoding CRISPR related proteins including dCAS9 and synthetic sgRNAs targeting a gene of interest.
    Type: Application
    Filed: May 25, 2021
    Publication date: April 14, 2022
    Inventors: Stephen G. HOGE, Eric Yi-Chun HUANG, Tirtha CHAKRABORTY
  • Patent number: 11268077
    Abstract: Materials and methods for treating a patient with hemoglobinopathy, both ex vivo and in vivo and materials and methods for deleting at least a portion of a human beta globin locus on chromosome 11 in a human cell by genome editing and thereby increasing the production of fetal hemoglobin (HbF).
    Type: Grant
    Filed: February 5, 2019
    Date of Patent: March 8, 2022
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Tirtha Chakraborty, Bibhu Prasad Mishra
  • Publication number: 20210299278
    Abstract: The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of polynucleotides, primary transcripts and mmRNA molecules.
    Type: Application
    Filed: September 14, 2020
    Publication date: September 30, 2021
    Inventors: Stephane BANCEL, Tirtha CHAKRABORTY, Antonin DE FOUGEROLLES, Sayda M. ELBASHIR, Matthias JOHN, Atanu ROY, Susan WHORISKEY, Kristy M. WOOD, Paul HATALA, Jason P. SCHRUM, Kenechi EJEBE, Jeff Lynn ELLSWORTH, Justin GUILD
  • Publication number: 20210260097
    Abstract: The disclosure features methods of reducing or inhibiting an anti-drug antibody response in a subject, as well as methods of reducing or inhibiting unwanted immune cell activation in a subject to be treated with a messenger RNA (mRNA), comprising administering to the subject a mRNA, e.g., a chemically modified messenger RNA (mmRNA), encoding a polypeptide of interest, wherein the mRNA comprises at least one microRNA (miR) binding site for a miR expressed in immune cells, such as miR-126 binding site and/or miR-142 binding site, such that an anti-drug antibody response to the polypeptide or interest, or unwanted immune cell activation (e.g., B cell activation, cytokine secretion), is reduced or inhibited in the subject. The disclosure further provides therapeutic treatment regimens designed to reduce or inhibit ADA or unwanted immune cell activation (e.g., B cell activation, cytokine secretion) in a subject being treated with mRNA-based therapeutics.
    Type: Application
    Filed: September 29, 2020
    Publication date: August 26, 2021
    Inventors: Stephen HOGE, Tirtha CHAKRABORTY, Gilles BESIN, Ruchi JAIN
  • Publication number: 20210180091
    Abstract: Provided are materials and methods for treating patients with hemoglobinopathies, either ex vivo or in vivo. Also provided are materials and methods for deleting and/or mutating a portion of a human beta globin locus on chromosome 11 and one or more of: a BCL11 A gene on chromosome 2, and a DNA sequence that encodes a transcriptional control region of the BCL11 A gene on chromosome 2, in a human cell by genome editing and thereby increasing the production of fetal hemoglobin (HbF) in the genome-edited human cells.
    Type: Application
    Filed: October 26, 2018
    Publication date: June 17, 2021
    Applicant: Vertex Pharmaceuticals Incorporated
    Inventors: Tirtha Chakraborty, Bibhu Prasad Mishra, Chad Albert Cowan, Ante Sven Lundberg, Samarth Kulkarni, Todd Douglass Borland
  • Patent number: 11027025
    Abstract: The present invention relates to compositions comprising and methods of using synthetic polynucleotides, e.g., modified mRNA, encoding CRISPR related proteins including dCAS9 and synthetic sgRNAs targeting a gene of interest.
    Type: Grant
    Filed: July 11, 2014
    Date of Patent: June 8, 2021
    Assignee: ModernaTX, Inc.
    Inventors: Stephen G. Hoge, Eric Yi-Chun Huang, Tirtha Chakraborty
  • Publication number: 20210115101
    Abstract: The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of polynucleotides, primary transcripts and mmRNA molecules.
    Type: Application
    Filed: October 28, 2019
    Publication date: April 22, 2021
    Inventors: Stephane BANCEL, Tirtha CHAKRABORTY, Antonin DE FOUGEROLLES, Sayda M. ELBASHIR, Matthias JOHN, Atanu ROY, Susan WHORISKEY, Kristy M. WOOD, Paul HATALA, Jason P. SCHRUM, Kenechi EJEBE, Jeff Lynn ELLSWORTH, Justin GUILD
  • Patent number: 10925935
    Abstract: The invention relates to compositions and methods for the manufacture and optimization of modified mRNA molecules via optimization of their terminal architecture.
    Type: Grant
    Filed: October 5, 2018
    Date of Patent: February 23, 2021
    Assignee: ModernaTX, Inc.
    Inventors: Tirtha Chakraborty, Stephane Bancel, Stephen G. Hoge, Atanu Roy, Antonin De Fougerolles, Noubar B. Afeyan
  • Publication number: 20200384033
    Abstract: Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.
    Type: Application
    Filed: December 5, 2018
    Publication date: December 10, 2020
    Applicant: Vertex Pharmaceuticals Incorporated
    Inventors: Ewelina Morawa, Tirtha Chakraborty, Ante Sven Lundberg, Tony Ho, Laura Sandler, Brenda Eustace, Jerome Rossert, Robert Kauffman
  • Patent number: 10849920
    Abstract: The disclosure features methods of reducing or inhibiting an anti-drug antibody response in a subject, as well as methods of reducing or inhibiting unwanted immune cell activation in a subject to be treated with a messenger RNA (mRNA), comprising administering to the subject a mRNA, e.g., a chemically modified messenger RNA (mmRNA), encoding a polypeptide of interest, wherein the mRNA comprises at least one microRNA (miR) binding site for a miR expressed in immune cells, such as miR-126 binding site and/or miR-142 binding site, such that an anti-drug antibody response to the polypeptide or interest, or unwanted immune cell activation (e.g., B cell activation, cytokine secretion), is reduced or inhibited in the subject. The disclosure further provides therapeutic treatment regimens designed to reduce or inhibit AD A or unwanted immune cell activation (e.g., B cell activation, cytokine secretion) in a subject being treated with mRNA-based therapeutics.
    Type: Grant
    Filed: October 5, 2016
    Date of Patent: December 1, 2020
    Assignee: ModernaTX, Inc.
    Inventors: Stephen Hoge, Tirtha Chakraborty, Gilles Besin, Ruchi Jain
  • Publication number: 20200330609
    Abstract: Materials and methods for treating a patient with a hemoglobinopathy, both ex vivo and in vivo, and materials and methods for deleting, modulating, or inactivating a transcriptional control sequence of a BCL11A gene in a cell by genome editing.
    Type: Application
    Filed: April 18, 2017
    Publication date: October 22, 2020
    Applicant: CRISPR Therapeutics AG
    Inventors: Chad Albert Cowan, Ante Sven Lundberg, Tirtha Chakraborty, Michelle l-ching Lin, Bibhu Prasad Mishra, Elizabeth Jae-eun Paik, Andrew Kernytsky, Todd Douglass Borland
  • Patent number: 10772975
    Abstract: The invention relates to a pharmaceutical composition including a plurality of lipid nanoparticles having a mean particle size of between 80 nm and 160 nm and containing an mRNA encoding a polypeptide. The lipid nanoparticles include a cationic lipid, a neutral lipid, a cholesterol, and a PEG lipid. The mRNA contains a 5?-cap, 5?-UTR, a 3?-UTR, and a poly-A region with at least 100 nucleotides.
    Type: Grant
    Filed: October 23, 2017
    Date of Patent: September 15, 2020
    Assignee: ModernaTX, Inc.
    Inventors: Stephane Bancel, Tirtha Chakraborty, Antonin De Fougerolles, Sayda M. Elbashir, Matthias John, Atanu Roy, Susan Whoriskey, Kristy M. Wood, Paul Hatala, Jason P. Schrum, Kenechi Ejebe, Jeff Lynn Ellsworth, Justin Guild
  • Publication number: 20190290742
    Abstract: The invention relates to compositions and methods for the manufacture and optimization of modified mRNA molecules via optimization of their terminal architecture.
    Type: Application
    Filed: October 5, 2018
    Publication date: September 26, 2019
    Applicant: ModernaTX, Inc.
    Inventors: Tirtha CHAKRABORTY, Stephane BANCEL, Stephen G. HOGE, Atanu ROY, Antonin DE FOUGEROLLES, Noubar B. AFEYAN
  • Publication number: 20190284542
    Abstract: Materials and methods for treating a patient with a hemoglobinopathy, both ex vivo and in vivo, and materials and methods for creating permanent changes to the genome that can result in at least one deletion, insertion, modulation, or inactivation of a transcriptional control sequence of a BCL11A gene in a cell by genome editing.
    Type: Application
    Filed: February 5, 2019
    Publication date: September 19, 2019
    Applicant: CRISPR Therapeutics AG
    Inventors: Tirtha Chakraborty, Michelle I-Ching Lin
  • Publication number: 20190256829
    Abstract: Materials and methods for treating a patient with hemoglobinopathy, both ex vivo and in vivo and materials and methods for deleting at least a portion of a human beta globin locus on chromosome 11 in a human cell by genome editing and thereby increasing the production of fetal hemoglobin (HbF).
    Type: Application
    Filed: February 5, 2019
    Publication date: August 22, 2019
    Applicant: CRISPR Therapeutics AG
    Inventors: Tirtha Chakraborty, Bibhu Prasad Mishra
  • Publication number: 20190240351
    Abstract: The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of polynucleotides, primary transcripts and mmRNA molecules.
    Type: Application
    Filed: October 20, 2017
    Publication date: August 8, 2019
    Inventors: Stephane BANCEL, Tirtha CHAKRABORTY, Antonin DE FOUGEROLLES, Sayda M. ELBASHIR, Jeff Lynn ELLSWORTH, Kenechi EJEBE, Justin GUILD, Matthias JOHN, Paul HATALA, Atanu ROY, Jason P. SCHRUM, Susan WHORISKEY, Kristy M. WOOD
  • Publication number: 20190201553
    Abstract: Materials and methods for treating a patient with a hemoglobinopathy, both ex vivo and in vivo, and materials and methods for deleting, modulating, or inactivating a transcriptional control sequence of a BCL11A gene in a cell by genome editing.
    Type: Application
    Filed: March 18, 2019
    Publication date: July 4, 2019
    Applicant: CRISPR Therapeutics AG
    Inventors: Chad Albert Cowan, Ante Sven Lundberg, Tirtha Chakraborty, Michelle I-ching Lin, Bibhu Prasad Mishra, Elizabeth Jae-eun Paik, Andrew Kernytsky, Todd Douglas Borland
  • Publication number: 20190185529
    Abstract: The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of signal-sensor polynucleotides, primary transcripts and mmRNA molecules.
    Type: Application
    Filed: July 16, 2018
    Publication date: June 20, 2019
    Inventors: Stephen G. Hoge, Tirtha Chakraborty, Joshua P. Frederick, Matthias John, Antonin De Fougerolles
  • Publication number: 20190085368
    Abstract: Described are methods for production of RNA transcripts using a non-amplified, linearized DNA tempate in an in vitro transcription reaction. Enzymatic 5? capping and oligo dT purification can also be included in the methods.
    Type: Application
    Filed: September 27, 2018
    Publication date: March 21, 2019
    Inventors: Stephane BANCEL, William Joseph ISSA, John Grant AUNINS, Tirtha CHAKRABORTY
  • Patent number: 10155029
    Abstract: The invention relates to compositions and methods for the manufacture and optimization of modified mRNA molecules via optimization of their terminal architecture.
    Type: Grant
    Filed: February 10, 2017
    Date of Patent: December 18, 2018
    Assignee: ModernaTX, Inc.
    Inventors: Tirtha Chakraborty, Stephane Bancel, Stephen G. Hoge, Atanu Roy, Antonin De Fougerolles, Noubar B. Afeyan